Study wrapper · #989
Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF.
Schauer A, Jahn D, Vahle B, et al. International journal of molecular sciences. 2026.
DOI: 10.3390/ijms27021060PubMed: 41596703
Editor's note
An animal study in obese ZSF1 rats where elamipretide improved mitochondrial respiration but did not translate into functional or structural cardiac improvement, and systolic performance modestly declined. A notable negative finding for the peptide in established HFpEF, a valuable counterweight to more optimistic preclinical reports.
Plain-language abstract
In a rat model of heart failure with preserved ejection fraction, elamipretide modestly improved mitochondrial respiration but produced no functional or structural heart benefits.
Related coverage
Weak / none
Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.
Tissue & celln=——2026
Weak / none
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.
Journal of radiation researchn=——2026
Supported
Elamipretide: a mitochondria-targeting drug for Barth syndrome.
Trends in pharmacological sciencesn=——2026